Dual bronchodilator versus inhaled corticosteroid/long-acting β2-agonist in patients with chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials.

CONCLUSIONS: Dual bronchodilator is superior to ICS/LABA in improving lung function and is associated with a lower risk of pneumonia in patients with COPD. There are no significant differences in other efficacy and safety profiles between these two maintenance treatments. PMID: 33601247 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33601247?dopt=Abstract

Source: International Immunopharmacology - February 15, 2021 Category: Allergy & Immunology Authors: Chen H, Wang K, Yuan T, Wang X, Huanng L, Jiang Z, Chen K, Du Y Tags: Int Immunopharmacol Source Type: research